Liarozole API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Liarozole API 115575-11-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Liarozole. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Liarozole
- Synonyms:
- Cas Number:
- 115575-11-6
- DrugBank number:
- DB13066
- Unique Ingredient Identifier:
- K0Q29TGV9Y
General Description:
Liarozole, identified by CAS number 115575-11-6, is a notable compound with significant therapeutic applications. Liarozole has been used in trials studying the treatment of Ichthyosis, Lamellar.
Classification:
Liarozole belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds), classified under the direct parent group Benzimidazoles. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzimidazoles class, specifically within the None subclass.
Categories:
Liarozole is categorized under the following therapeutic classes: Antineoplastic Agents, Antineoplastic Agents, Hormonal, Dermatologicals, Enzyme Inhibitors, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Liarozole is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
